Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rizatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 6/20 | 0.86 |
| ▸ | HTR1B known ✓ | P28222 | 6/20 | 0.86 |
| ▸ | HTR1A | P08908 | 13/20 | 0.86 |
| ▸ | HTR2C | P28335 | 8/20 | 0.86 |
| ▸ | HTR2A | P28223 | 3/20 | 0.86 |
| ▸ | HTR2B | P41595 | 3/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.86 |
| ▸ | HRH1 | P35367 | 1/20 | 0.86 |
| ▸ | HTR5A | P47898 | 4/20 | 0.53 |
| ▸ | HTR1E | P28566 | 1/20 | 0.53 |
| ▸ | HTR1F | P30939 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rizatriptan SCHEMBL2231061 | 0.99 | HTR1A (0.88) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL26662 | 0.93 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL12802834 | 0.93 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL29407208 | 0.93 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL8809854 | 0.92 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL8809846 | 0.92 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL28815652 | 0.92 | HTR1A (0.98) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL28840728 | 0.91 | HTR1A (0.88) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL3462253 | 0.89 | HTR1A (0.85) | HTR1AHTR2CHTR1DHTR1BHTR2A | |
| Rizatriptan SCHEMBL2326617 | 0.89 | HTR1A (0.83) | HTR1AHTR2CHTR1DHTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986472-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254603-A1 | CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254606-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| EP-2525830-B1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2016-05-11 | — | — | EP | disclosed |
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2015-07-23 | — | — | US | disclosed |
| US-9062094-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2015-06-23 | — | — | US | disclosed |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-5981526-A | SYNERGISTIC TREATMENT OR PREVENTION OF MIGRAINE | MERCK SHARP & DOHME LTD. (GB) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | HTR1D 3340/4885HTR1B 2974/4885HTR1A 3275/4885 |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | HTR1D 3340/4885HTR1B 2974/4885HTR1A 3275/4885 |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, ABCB1, NCL | HTR1D 1662/4885HTR1B 1061/4885HTR1A 845/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | HTR1D 1900/4885HTR1B 1323/4885HTR1A 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.